Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2022-06-16 00:00:00 ET · period of report 2022-06-14 · accession 0001209191-22-037399 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-16 | 2022-06-14 | PCRX | LARANJEIRA CHARLES ANTHONY | Chief Technical Off | M - OptEx | $38.35 | +6,000 | 41.8K | +17% | +$230.1K |
| D | 2022-06-16 | 2022-06-14 | PCRX | LARANJEIRA CHARLES ANTHONY | Chief Technical Off | M - OptEx | $0.00 | -6,000 | 9,000 | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-14 | M | A | 6,000 | $38.35 | 41,752 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-14 | M | D | 6,000 | $0.00 | 9,000 | D | $38.35 · — to 2028-06-13 | 6,000 Common Stock | (F2) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |